These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1108 related articles for article (PubMed ID: 20674596)
21. FDA Modernization Act: implications for oncology. Morris L Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506 [TBL] [Abstract][Full Text] [Related]
22. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule. Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560 [TBL] [Abstract][Full Text] [Related]
23. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
24. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment. Roller ST; Pippins RR; Ngai JW Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646 [TBL] [Abstract][Full Text] [Related]
25. The food and drug administration and molecular imaging agents: potential challenges and opportunities. Henderson JA; Alexander BC; Smith JJ J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943 [TBL] [Abstract][Full Text] [Related]
26. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care. Watson KT; Barash PG Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852 [TBL] [Abstract][Full Text] [Related]
27. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective. Schwieterman WD Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146 [TBL] [Abstract][Full Text] [Related]
32. The NCI All Ireland Cancer Conference. Johnston PG; Daly PA; Liu E Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862 [TBL] [Abstract][Full Text] [Related]
33. Drug regulation and policy formulation. Nightingale SL Milbank Mem Fund Q Health Soc; 1981; 59(3):412-44. PubMed ID: 7024847 [TBL] [Abstract][Full Text] [Related]
34. Current good manufacturing practice regulation and investigational new drugs. Direct final rule. Food and Drug Administration. HHS Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693 [TBL] [Abstract][Full Text] [Related]
35. How drugs are developed and approved by the FDA: current process and future directions. Ciociola AA; Cohen LB; Kulkarni P; Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999 [TBL] [Abstract][Full Text] [Related]
36. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule. Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618 [TBL] [Abstract][Full Text] [Related]
38. What's next after 50 years of psychiatric drug development: an FDA perspective. Laughren TP J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624 [TBL] [Abstract][Full Text] [Related]
39. Regulation of research: is it a drug trial or a supplement trial? Chen ST Fitoterapia; 2011 Jan; 82(1):14-6. PubMed ID: 21073930 [TBL] [Abstract][Full Text] [Related]
40. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy. Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]